Literature DB >> 8166528

Cerebral imaging in the asymptomatic preoperative bronchogenic carcinoma patient: is it worthwhile?

F H Cole1, J E Thomas, A B Wilcox, H H Halford.   

Abstract

The issue of screening for cerebral metastatic disease in the preoperative bronchogenic carcinoma patient remains unsettled and changes with advancing technology. A prospective nonrandomized study was designed to compare contrast magnetic resonance imaging (MRI) with computed tomography (CT) after several clinical situations suggested improved sensitivity for the former study. Patients with clinically operable disease and normal neurologic examinations were referred for both enhanced cerebral CT and MRI studies. Forty-two patients were entered and completed the enhanced CT scan; only 30 tolerated the MRI. The demographic data and histology of the patients appeared fairly typical for a series of operative candidates. No unsuspected metastatic lesion was found in this selected and low-risk group. We conclude that neither MRI nor enhanced CT scan is indicated in the asymptomatic bronchogenic carcinoma patient due to expense and lack of positive findings. Magnetic resonance imaging demonstrated more subtle benign pathology, but this study did not allow comparison of the two techniques in detection of metastatic disease.

Entities:  

Mesh:

Year:  1994        PMID: 8166528     DOI: 10.1016/0003-4975(94)90185-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Comparative study of vascular enhancement on post-contrast CT using three dosages of iodinated contrast media for the aim of detecting brain metastasis in patients with lung cancer.

Authors:  Katsumi Hayakawa; Toshiki Shiozaki; Akira Yamamoto; Soichi Kubo; Tsutomu Osako
Journal:  Radiat Med       Date:  2006-02

2.  Screening of brain metastasis with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients.

Authors:  Sun Young Kim; Jae Sung Kim; Hee Sun Park; Moon June Cho; Ju Ock Kim; Jin Whan Kim; Chang Jun Song; Seung Pyung Lim; Sung Soo Jung
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

3.  S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer.

Authors:  Humberto Choi; Vikram Puvenna; Chanda Brennan; Shamseldeen Mahmoud; Xiao-Feng Wang; Michael Phillips; Damir Janigro; Peter Mazzone
Journal:  Transl Lung Cancer Res       Date:  2016-08

4.  Early stage non-small cell lung cancer patients need brain imaging regardless of symptoms.

Authors:  Takahiro Ando; Hidenori Kage; Minako Saito; Yosuke Amano; Yasushi Goto; Jun Nakajima; Takahide Nagase
Journal:  Int J Clin Oncol       Date:  2018-02-26       Impact factor: 3.402

5.  Appropriateness of imaging for lung cancer staging in a national cohort.

Authors:  Leah M Backhus; Farhood Farjah; Thomas K Varghese; Aaron M Cheng; Xiao-Hua Zhou; Douglas E Wood; Larry Kessler; Steven B Zeliadt
Journal:  J Clin Oncol       Date:  2014-09-22       Impact factor: 44.544

6.  Impact of neuroimaging in the pretreatment evaluation of early stage non-small cell lung cancer.

Authors:  Garrett T Wasp; Christopher Del Prete; Jonathan A D Farrell; Konstantin H Dragnev; Gregory Russo; Graham T Atkins; Joseph D Phillips; Gabriel A Brooks
Journal:  Heliyon       Date:  2020-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.